

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1498)**

**CHANGE IN COMPOSITION OF  
THE NOMINATION COMMITTEE**

The board of directors (the “Board”) of PuraPharm Corporation Limited (the “Company”) announces that Dr. Chan Kin Keung, Eugene (“Dr. Chan”) has resigned as a member of the nomination committee of the Company but continues to serve as the chairman of the remuneration committee and a member of the audit committee.

The Board is pleased to announce that Prof. Tsui Lap Chee (“Prof. Tsui”), an independent non-executive director of the Company and a member of the remuneration committee, has been appointed as a member of the nomination committee to fill the vacancy left by Dr. Chan’s resignation, both with effect from 27 March 2019.

Prof. Tsui, aged 68, is currently the President of the Academy of Sciences of Hong Kong and the President of Victor and William Fung Foundation. He is also an independent non-executive director of Hang Lung Group Limited (stock code: 0010). Prior to joining the Company, he was the Vice Chancellor of the University of Hong Kong. Prof. Tsui has over 40 years of research work experience, particularly in human genetics and genomics. Besides, he has over 300 peer-reviewed scientific publications and 65 invited book chapters. He was the recipient of many national and international prizes and was awarded 16 honorary doctoral degrees from universities around the world. He was appointed as the Justice of the Peace in 2006 and was awarded the Gold Bauhinia Star and the Grand Bauhinia Medal by the Chief Executive of Hong Kong SAR in 2011 and 2016 respectively. He received a Doctor of Philosophy Degree from the University of Pittsburgh in the U.S..

As at the date of this announcement and within the meaning of Part XV of the SFO, Prof. Tsui is deemed to be interested in 20,000 Shares, representing approximately 0.01% of the entire issued share capital of the Company.

By order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

Hong Kong, 27 March 2019

*As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie, and Ms. Man Yee Wai, Viola; the non-executive director of the Company is Mr. Chow, Stanley; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*